107 related articles for article (PubMed ID: 21832259)
1. Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study.
Sziráki I; Erdo F; Beéry E; Molnár PM; Fazakas C; Wilhelm I; Makai I; Kis E; Herédi-Szabó K; Abonyi T; Krizbai I; Tóth GK; Krajcsi P
J Biomol Screen; 2011 Sep; 16(8):886-94. PubMed ID: 21832259
[TBL] [Abstract][Full Text] [Related]
2. The use of microdialysis techniques in mice to study P-gp function at the blood-brain barrier.
Sziráki I; Erdő F; Trampus P; Sike M; Molnár PM; Rajnai Z; Molnár J; Wilhelm I; Fazakas C; Kis E; Krizbai I; Krajcsi P
J Biomol Screen; 2013 Apr; 18(4):430-40. PubMed ID: 23204072
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
[TBL] [Abstract][Full Text] [Related]
4. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S
Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481
[TBL] [Abstract][Full Text] [Related]
5. In vivo induction of P-glycoprotein expression at the mouse blood-brain barrier: an intracerebral microdialysis study.
Chan GN; Saldivia V; Yang Y; Pang H; de Lannoy I; Bendayan R
J Neurochem; 2013 Nov; 127(3):342-52. PubMed ID: 23777437
[TBL] [Abstract][Full Text] [Related]
6. Impact of P-glycoprotein on blood-retinal barrier permeability: comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats.
Fujii S; Setoguchi C; Kawazu K; Hosoya K
Invest Ophthalmol Vis Sci; 2014 Jul; 55(7):4650-8. PubMed ID: 24985475
[TBL] [Abstract][Full Text] [Related]
7. Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats.
Bors LA; Bajza Á; Mándoki M; Tasi BJ; Cserey G; Imre T; Szabó P; Erdő F
Brain Res Bull; 2020 Jul; 160():65-73. PubMed ID: 32344126
[TBL] [Abstract][Full Text] [Related]
8. Blood-brain barrier models: in vitro to in vivo translation in preclinical development of CNS-targeting biotherapeutics.
Stanimirovic DB; Bani-Yaghoub M; Perkins M; Haqqani AS
Expert Opin Drug Discov; 2015 Feb; 10(2):141-55. PubMed ID: 25388782
[TBL] [Abstract][Full Text] [Related]
9. Platelet activating factor induces transient blood-brain barrier opening to facilitate edaravone penetration into the brain.
Fang W; Zhang R; Sha L; Lv P; Shang E; Han D; Wei J; Geng X; Yang Q; Li Y
J Neurochem; 2014 Mar; 128(5):662-71. PubMed ID: 24164378
[TBL] [Abstract][Full Text] [Related]
10. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs.
Cucullo L; Hossain M; Rapp E; Manders T; Marchi N; Janigro D
Epilepsia; 2007 Mar; 48(3):505-16. PubMed ID: 17326793
[TBL] [Abstract][Full Text] [Related]
11. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats.
Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T
Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062
[TBL] [Abstract][Full Text] [Related]
12. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
[TBL] [Abstract][Full Text] [Related]
13. Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model.
Vautier S; Milane A; Fernandez C; Buyse M; Chacun H; Farinotti R
Neurosci Lett; 2008 Sep; 442(1):19-23. PubMed ID: 18598736
[TBL] [Abstract][Full Text] [Related]
14. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
15. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain.
Sun H; Bungay PM; Elmquist WF
J Pharmacol Exp Ther; 2001 Jun; 297(3):991-1000. PubMed ID: 11356921
[TBL] [Abstract][Full Text] [Related]
16. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.
Keogh JP; Kunta JR
Eur J Pharm Sci; 2006 Apr; 27(5):543-54. PubMed ID: 16406207
[TBL] [Abstract][Full Text] [Related]
17. Abcb1a (P-glycoprotein) limits brain exposure of the anticancer drug candidate seliciclib in vivo in adult mice.
Erdő F; Nagy I; Tóth B; Bui A; Molnár É; Tímár Z; Magnan R; Krajcsi P
Brain Res Bull; 2017 Jun; 132():232-236. PubMed ID: 28629814
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide mediates cyclosporine-induced impairment of the blood-brain barrier in cocultures of mouse brain endothelial cells and rat astrocytes.
Dohgu S; Yamauchi A; Nakagawa S; Takata F; Kai M; Egawa T; Naito M; Tsuruo T; Sawada Y; Niwa M; Kataoka Y
Eur J Pharmacol; 2004 Nov; 505(1-3):51-9. PubMed ID: 15556136
[TBL] [Abstract][Full Text] [Related]
19. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening.
Culot M; Lundquist S; Vanuxeem D; Nion S; Landry C; Delplace Y; Dehouck MP; Berezowski V; Fenart L; Cecchelli R
Toxicol In Vitro; 2008 Apr; 22(3):799-811. PubMed ID: 18280105
[TBL] [Abstract][Full Text] [Related]
20. Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat.
Jalkanen AJ; Hakkarainen JJ; Lehtonen M; Venäläinen T; Kääriäinen TM; Jarho E; Suhonen M; Forsberg MM
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):443-51. PubMed ID: 21707925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
